NASDAQ$RPRX
Royalty Pharma PLC · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Royalty Pharma reported strong growth in the third quarter of 2021, driven by portfolio performance and new royalty acquisitions. The company raised its full-year 2021 guidance for Adjusted Cash Receipts.
Royalty Pharma reported a 9% increase in total income and other revenues to $586 million, driven by strong portfolio performance, new royalty acquisitions, and a one-time payment related to Soliqua. Adjusted Cash Receipts increased 24% to $587 million, and Adjusted Cash Flow grew 12% to $441 million.
- Net cash provided from operating activities (GAAP) was $470 million.
- Adjusted Cash Receipts (non-GAAP) increased 24% to $587 million.
- Adjusted Cash Flow (non-GAAP) grew 12% to $441 million.
- 2021 Adjusted Cash Receipts guidance raised to $2,110 to $2,130 million.
Headline financials
Revenue & EPS history
Royalty Pharma · Revenue · Quarterly
$586M
Revenue by segment
Royalty Pharma · $621M total across 11 segments · Q3 2021
- Cystic Fibrosis Franchise$183M+16.6%29.5%
- Other Products$124M+110.2%20.0%
- Tysabri$96M+24.7%15.5%
- Imbruvica$88M+12.8%14.2%
- Promacta$48M+20.0%7.7%
- Xtandi$40M+5.3%6.4%
- Tremfya$17M—2.7%
- Cabometyx/Cometriq$12M—1.9%
- Evrysdi$6M—1.0%
- Erleada$4M+100.0%0.6%
- Trodelvy$3M+200.0%0.5%
Forward guidance
Royalty Pharma anticipates 2021 Adjusted Cash Receipts to be between $2,110 million and $2,130 million, excluding new transactions announced after the date of this release. Payments for operating and professional costs will be approximately 9% of Adjusted Cash Receipts in 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-0.6%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+6.8%
Q3 2025
Best reaction
-8.1%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.0% | +2.4% | +10.7% | |
| Q4 2025 | +0.1% | +2.2% | +3.3% | |
| Q3 2025 | +6.8% | +1.8% | +5.0% | |
| Q1 2025 | +0.9% | +0.2% | +3.1% | |
| Q4 2024 | +1.7% | +2.0% | +3.0% | |
| Q3 2024 | -3.7% | -4.3% | -5.9% | |
| Q2 2024 | -3.6% | -1.4% | +5.3% | |
| Q1 2024 | +0.4% | +0.3% | -1.9% | |
| Q4 2023 | +2.1% | +3.4% | +2.7% | |
| Q3 2023 | -0.5% | -1.6% | +3.7% | |
| Q2 2023 | -0.9% | -1.1% | -6.4% | |
| Q1 2023 | -4.7% | -2.7% | -2.8% | |
| Q4 2022 | -2.0% | -0.4% | -8.8% | |
| Q3 2022 | +1.6% | +3.7% | -0.1% | |
| Q2 2022 | -0.9% | +1.9% | -1.8% | |
| Q1 2022 | -8.1% | -12.8% | -6.2% | |
| Q4 2021 | +3.6% | +0.8% | +1.7% | |
| Q3 2021 | +1.5% | +5.3% | -4.6% | |
| Q2 2021 | +2.7% | +5.0% | +5.6% | |
| Q1 2021 | -2.2% | -1.8% | +12.4% | |
| Q4 2020 | -2.1% | +1.1% | -1.5% | |
| Q3 2020 | -1.6% | +2.8% | +10.3% | |
| Q2 2020 | -3.0% | -4.2% | -5.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro